Skip to main content
Hanmi Pharm. Co., Ltd. logo

Hanmi Pharm. Co., Ltd. — Investor Relations & Filings

Ticker · 128940 ISIN · KR7128940004 LEI · 988400PP10VZVUOFE672 KO Manufacturing
Filings indexed 507 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 128940

About Hanmi Pharm. Co., Ltd.

https://www.hanmipharm.com/

Hanmi Pharm. Co., Ltd. is a research-oriented biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products. Its portfolio includes prescription drugs, over-the-counter (OTC) medicines, and raw materials. The company dedicates a significant portion of its revenue to in-house research and development, creating a robust pipeline of innovative therapies. A key unique selling point is its proprietary LAPSCOVERY platform technology, which is used to develop long-acting biologics. Hanmi's R&D efforts are concentrated on key therapeutic areas, including metabolic diseases, oncology, and rare diseases. The company actively collaborates with global partners to advance its clinical programs and bring novel treatments to the market.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서 (제17기 1분기)” covering the period Jan 1 2026 to Mar 31 2026 and contains extensive tables of quarterly financial data (revenues by product, segment information, capacity and production figures, risk management, etc.). It is the full interim/quarterly report itself (not a short notice or certification), matching the definition for an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-15 Korean
기업설명회(IR)개최(안내공시)
Regulatory Filings
2026-04-30 Korean
기업설명회(IR)개최(안내공시)
Regulatory Filings
2026-04-30 Korean
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Regulatory Filings
2026-04-30 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Regulatory Filings
2026-04-30 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 85% confidence The document is an announcement (안내공시) scheduling a corporate investor presentation (IR) to explain the Q1 2026 results via a conference call. It is explicitly about an Investor Relations Presentation event. There is no financial data itself or post-event materials; it’s purely an IR event notice, which falls under the Investor Presentation category (IP).
2026-04-23 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.